We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-12.68%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.45B
AUM Growth
-$497M
Cap. Flow
+$144M
Cap. Flow %
5.89%
Top 10 Hldgs %
73.47%
Holding
55
New
2
Increased
12
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$62.7M
2
KURA icon
Kura Oncology
KURA
+$40.4M
3
AXSM icon
Axsome Therapeutics
AXSM
+$34.4M
4
RVMD icon
Revolution Medicines
RVMD
+$32.5M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$28.3M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$35.3M
2
ETNB
89bio
ETNB
+$33.9M
3
GHRS icon
GH Research
GHRS
+$17.6M
4
XOMA
Xoma
XOMA
+$15.7M
5
ENGN icon
enGene Therapeutics
ENGN
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NCEL
51
NewcelX Ltd
NCEL
$18.7M
$221K 0.01%
14,368
– –
AGIO icon
52
Agios Pharmaceuticals
AGIO
$1.86B
– –
-1,073,755
Closed -$35.3M
ELEV
53
DELISTED
Elevation Oncology
ELEV
– –
-2,966,836
Closed -$1.67M
ENGN icon
54
enGene Therapeutics
ENGN
$117M
– –
-2,106,037
Closed -$14M
ETNB
55
DELISTED
89bio
ETNB
– –
-4,333,885
Closed -$33.9M
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2025 Portfolio in Review

As of Q1 2025, BVF Inc held 55 positions worth $2.45B, down 17% from $2.95B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

BVF Inc deployed $144M of net new capital in Q1 2025, opening 2 new positions and adding to 12 existing holdings. Its largest new stake was Ionis Pharmaceuticals: 1,913,385 shares worth $57.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was GH Research, an estimated $17.6M trimmed.

  • BVF Inc's largest Q1 2025 buy was Ionis Pharmaceuticals: 1,913,385 shares worth $57.7M.
  • BVF Inc added most to Kura Oncology in Q1 2025, an estimated $40.4M increase.
  • BVF Inc's biggest Q1 2025 reduction was GH Research, cutting an estimated $17.6M.
  • BVF Inc fully exited Agios Pharmaceuticals in Q1 2025, selling an estimated $35.3M.
  • BVF Inc's ten largest holdings make up 73% of its $2.45B portfolio in Q1 2025.
  • BVF Inc opened 2 new positions and closed 4 in Q1 2025.
  • BVF Inc's portfolio value fell 17% quarter-over-quarter to $2.45B.

Based on BVF Inc's 13F filing for Q1 2025, filed 15 May 2025.